sphingotest® biomarker assays

sphingotest® bio-ADM

A Marker for Acute Circulatory Failure

Prediction, Diagnosis and Monitoring of Acute Circulatory Failure

sphingotec
Innovations for life

To predict, diagnose and monitor acute circulatory failure

sphingotest® bio-ADM is the only immunoassay to measure the plasma level of biological active Adrenomedullin (ADM), in contrast to methods that detect inactive precursor fragments of ADM, that are not suitable for timely monitoring.

Adrenomedullin is a vasodilatory hormone that regulates blood pressure and plays an essential role in the development of acute circulatory failure. bio-ADM is a valuable biomarker for the prediction, diagnosis and monitoring of acute circulatory failure, e.g. septic shock.

Simple validated cut-off



To support early intervention in acute circulatory failure

bio-ADM identifies patients that are likely to develop a circulatory failure in the near future – supporting timely management of patients with high risk of shock, e.g. in sepsis.

Recent studies show a compelling relationship between the time to initiate vasopressor therapy and shock survival: The earlier the patient recieves vasopressors, the higher is the survival rate.

Prediction and diagnosis



To improve shock management and hospital outcome

Serial bio-ADM measurement enables close monitoring of the change in risk of acute circulatory failure and monitoring of shock treatment.

bio-ADM level show if a patient is responding to the treatment, thereby supporting patient management and discharge decision.

Monitoring



sphingotest® bio-ADM: A dynamic marker for vascular integrity

Reliable

- Worldwide validated in ten-thousands of patients
- Simple and robust cut-off
- Independent of comorbidities and inflammation

Practical

- Blood e.g. plasma as sample matrix
- Stable at room temperature
- 1 hour to result

Valuable

- Prediction of acute circulatory failure enables earlier treatment, e.g. vasopressor therapy
- Close monitoring supports patient management and discharge decision

sphingotest®
acute biomarkers

- Early prediction for early intervention
- Close monitoring for discharge decision
- Unaffected by comorbidities and inflammation
- Simple and robust cut-off
- Easy handling of blood samples

sphingotest® bio-ADM

Prediction, Diagnosis and Monitoring
of Acute Circulatory Failure e.g. in Sepsis and
Incomplete Decongestion in Acute Heart Failure

sphingotest® penKid

Prediction, Diagnosis and Monitoring
of Acute Kidney Injury

For further information please contact:

+49 3302 20565-0 | info@sphingotec.de

sphingotec GmbH
Neuendorfstrasse 15A | 16761 Hennigsdorf | Germany | www.sphingotec.com

sphingotec
Innovations for life